2024 NOSCM | Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)

2024 NOSCM | Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)

0% Complete

Course Overview

NA

Course Content

Course Details

Duration
0.00 hour
Released
May 14, 2025
Last Review
May 14, 2025
Expires
May 14, 2028

Objectives

NA

Target Audience

NA

Faculty & Disclosure

Faculty

Lajos Puzstai, MD, DPhil, FASCO

Disclosure

Lajos Puzstai, MD, DPhil, FASCO discloses no such relationships exist

Accreditation

NA